A study at the University of Nebraska Medical Center (UNMC) found that a novel device can significantly reduce contamination of blood cultures, potentially reducing risky overtreatment and unnecessary use of antibiotics for many patients. This approach could also substantially reduce health care costs, according to the study.
Thousands of U.S. patients get their blood drawn every day for blood cultures in order to diagnose serious infections such as sepsis, which can be a deadly condition. A small but significant percentage of the blood cultures are contaminated, due in part to skin fragments containing bacteria that are dislodged during a blood draw.
This leads to false results that can mislead clinicians into thinking a patient has a potentially serious bloodstream infection. The consequences are costly and put patients at risk.
With traditional blood draws, about 30% to 40% of patients with contaminated blood cultures are prescribed antibiotics unnecessarily. This contributes to antibiotic resistance and undermines nationwide efforts to improve antimicrobial stewardship. A large number of patients get another unnecessary blood draw. For many patients, the risks include an extended hospital stay and potential side effects of antibiotics.
“A lot of people think this is a minor problem,” said lead author Mark Rupp, MD, professor and chief of the UNMC Division of Infectious Diseases and medical director of the Department of Infection Control and Epidemiology at Nebraska Medicine, UNMC’s hospital partner. “However, contaminated blood cultures are a big deal. Physicians can be led astray, and patients may be harmed by additional tests and unnecessary antimicrobial therapy.”
The prospective, controlled study, conducted with 904 patients and 1,808 blood cultures, compared standard procedures to the SteriPath initial specimen diversion device (ISDD) to determine whether blood culture contamination was reduced. The ISDD is a sterile blood collection system that diverts and sequesters the first 1.5 to 2.0 mL of blood—which often carries contaminating skin cells and microbes. This part of the blood is discarded.
Blood culture contamination was significantly reduced through use of the ISDD.
“We were able to decrease the false positive rate significantly through use of this device—from 1.78% down to 0.2%, which represents an 88% reduction,” Dr. Rupp said. “The 1.78% baseline rate of contamination may seem small, but we should strive to decrease adverse events to the lowest possible level because of the impact to the patient and the burden to our health care system. We quite clearly showed the rate of contamination was significantly reduced, and that decrease has a very big impact.”
He said contamination rates routinely range from 0.6% to 6.0 % in U.S. health care institutions.
Costs associated with blood culture contamination per patient case ranged from $1,000 in 1998 to $8,700 in 2009. A more recent study in the United States observed excess charges of $8,720 per contamination event.
“If a midpoint cost estimate of $4,850 is used, and the added cost of the device is not taken into account, it equates to a cost avoidance of $1.8 million per year at our institution alone,” Dr. Rupp said. “If the low rate of contamination that we observed in the study, 0.22%, was applied to all blood cultures throughout the country, billions of dollars of excess costs could be avoided.”
The results of the study are published online in the journal Clinical Infectious Diseases.
The study was supported by Magnolia Medical Technologies, Inc., through a research contract.
Source: UNMC; May 17, 2017.